Literature DB >> 15954144

NeuroAIDS: contributions of the human immunodeficiency virus-1 proteins Tat and gp120 as well as CD40 to microglial activation.

T G D'Aversa1, E A Eugenin, J W Berman.   

Abstract

Microglia are the resident phagocytes of the brain and are an important source of proinflammatory mediators. Human immunodeficiency virus (HIV)-1 infects the central nervous system early in the course of disease, and it is believed that this occurs, in part, through the transmigration of HIV-1-infected cells across the blood-brain barrier. Infected cells release viral proteins, such as Tat and gp120. After microglia interact with these proteins, they become activated and secrete chemokines; up-regulate key surface receptors, such as CD40, and also activate resident cells. This review focuses on the consequences of microglial activation in NeuroAIDS, with an emphasis on chemokine production and CD40 up-regulation after interaction with tat or gp120. The importance of microglial CD40 in two other neurological diseases, Alzheimer's disease and multiple sclerosis, is also discussed. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15954144     DOI: 10.1002/jnr.20486

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  44 in total

1.  Nanomedicine in the diagnosis and therapy of neurodegenerative disorders.

Authors:  A V Kabanov; H E Gendelman
Journal:  Prog Polym Sci       Date:  2007       Impact factor: 29.190

2.  Preferential sensitivity of human dopaminergic neurons to gp120-induced oxidative damage.

Authors:  Shuxian Hu; Wen S Sheng; James R Lokensgard; Phillip K Peterson; R Bryan Rock
Journal:  J Neurovirol       Date:  2009-09       Impact factor: 2.643

3.  Lipopolysaccharide is a frequent and significant contaminant in microglia-activating factors.

Authors:  Jonathan R Weinstein; Sarah Swarts; Caroline Bishop; Uwe-Karsten Hanisch; Thomas Möller
Journal:  Glia       Date:  2008-01-01       Impact factor: 7.452

4.  Morphine and HIV-Tat increase microglial-free radical production and oxidative stress: possible role in cytokine regulation.

Authors:  Jadwiga Turchan-Cholewo; Filomena O Dimayuga; Sunita Gupta; Jeffrey N Keller; Pamela E Knapp; Kurt F Hauser; Annadora J Bruce-Keller
Journal:  J Neurochem       Date:  2008-11-19       Impact factor: 5.372

5.  Human immunodeficiency virus type 1 subtype C Tat fails to induce intracellular calcium flux and induces reduced tumor necrosis factor production from monocytes.

Authors:  Grant R Campbell; Jennifer D Watkins; Kumud K Singh; Erwann P Loret; Stephen A Spector
Journal:  J Virol       Date:  2007-03-21       Impact factor: 5.103

6.  Shedding of PECAM-1 during HIV infection: a potential role for soluble PECAM-1 in the pathogenesis of NeuroAIDS.

Authors:  E A Eugenin; R Gamss; C Buckner; D Buono; R S Klein; E E Schoenbaum; T M Calderon; J W Berman
Journal:  J Leukoc Biol       Date:  2006-01-13       Impact factor: 4.962

7.  Critical Role of Beclin1 in HIV Tat and Morphine-Induced Inflammation and Calcium Release in Glial Cells from Autophagy Deficient Mouse.

Authors:  Jessica Lapierre; Myosotys Rodriguez; Chet Raj Ojha; Nazira El-Hage
Journal:  J Neuroimmune Pharmacol       Date:  2018-05-11       Impact factor: 4.147

8.  SOLUBLE CD40 LIGAND IN DEMENTIA.

Authors:  B Giunta; K P Figueroa; T Town; J Tan
Journal:  Drugs Future       Date:  2009-04-01       Impact factor: 0.148

9.  Increased in vivo activation of microglia and astrocytes in the brains of mice transgenic for an infectious R5 human immunodeficiency virus type 1 provirus and for CD4-specific expression of human cyclin T1 in response to stimulation by lipopolysaccharides.

Authors:  Jinglin Sun; Jian Hua Zheng; Mengliang Zhao; Sunhee Lee; Harris Goldstein
Journal:  J Virol       Date:  2008-03-19       Impact factor: 5.103

10.  Differences in NMDA receptor expression during human development determine the response of neurons to HIV-tat-mediated neurotoxicity.

Authors:  E A Eugenin; J E King; J E Hazleton; E O Major; M V L Bennett; R S Zukin; Joan W Berman
Journal:  Neurotox Res       Date:  2010-01-22       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.